Skip to main content

Table 2 BPRS total scores and scores of each factor for different treatment periods

From: Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China

Item

Before treatment

(n = 364)

2–4 weeks of treatment

(n = 362)

6–8 weeks of treatment

(n = 349)

12 weeks of treatment

(n = 322)

Anxiety-depression

10.0 ± 3.45

8.0 ± 2.75**

6.8 ± 2.49**

5.8 ± 1.96**

Anergia

10.2 ± 3.12

8.4 ± 2.55**

7.2 ± 2.39**

6.2 ± 2.03**

Thought disturbance

12.7 ± 4.08

9.5 ± 3.52**

7.7 ± 3.09**

6.3 ± 2.58**

Activation

6.6 ± 2.81

4.8 ± 1.97**

4.1 ± 1.50**

3.6 ± 1.21**

Hostility-suspiciousness

10.6 ± 3.78

7.3 ± 2.78**

5.8 ± 2.41**

4.7 ± 1.81**

BPRS total score

50.1 ± 11.95

38.0 ± 9.68**

31.5 ± 8.98**

26.6 ± 7.43**

  1. BPRS brief psychiatric rating scale
  2. **Compared to baseline, P < 0.001